Pieter Slegers — Should you buy LeMaitre Vascular? (Compounding Quality)

One-line take: the January run's only piece of primary research, and the archive's best small-cap worked example of the 15-step worksheet. LeMaitre Vascular ($LMAT) makes over 100 devices for surgery on blood vessels outside the heart and brain — grafts, stents, patches, balloons, and the valvulotome the founder invented in 1983 — and has quietly turned $10,000 into $161,460 since its 2006 IPO against the S&P 500's $98,690, a 15.5% CAGR. The moat argument is the interesting part: it is niche size, deliberately. "Rather than competing head-on with medtech giants like Medtronic or Boston Scientific, they focus solely on an interesting niche market… too small for the giants, but too complex for generic manufacturers," reinforced by FDA/CE approval costs and the fact that "switching suppliers means retesting, retraining, and risking patient safety." On top of that sits a 30+ subsidiary roll-up — a serial acquirer in a fragmented niche, sold through a 100-strong salesforce. The numbers back it: 71.0% gross margin, 21.3% ROIC, 22.1% net margin, FCF/net income 124.2%, net cash, CAPEX 2.9% of sales, revenue +14.6% and EPS +20.6% a year over five. Three thresholds fail, and they are the ones that matter for the answer: ROE 14.9% against a >20% bar, SBC at 14.0% of net income (15.6% on a five-year average) against a <10% bar, and a reverse DCF requiring 16.1% annual FCF growth for a decade — marked "realistic growth expectations? ❌" by the author himself. Two of the three valuation methods pass (32.5x forward against a 38.0x ten-year average; an Earnings Growth Model return of 11.7%) and the third does not, which is exactly the split that produces a Total Quality Score of 8.0/10 and a conclusion that praises the business — "Lemaitre Vascular is an amazing company" — without ever saying buy. Note the context: this is a Tiny Titans piece, the closed small-cap product, not a Portfolio candidate.

1. Stocks & names mentioned

One subject company; Medtronic and Boston Scientific appear only as the giants LeMaitre deliberately does not compete with, and get no row. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. Written post with no timestamps — the At link opens the article.

Ticker	Name	Research	View	What he said	At
LMAT	LeMaitre Vascular	QT · SA · STK · FA	Positive	Total Quality Score 8.0/10, at $83.9 and a $1.9bn market cap. "One of the best compounders you've never heard of… While others looked elsewhere, LeMaitre compounded quietly and massively outperformed the S&P 500" — $10,000 → $161,460 since the 2006 IPO (15.5% CAGR) versus $98,690 for the index. Classified as an Owner-Operator: founded 1983 by vascular surgeon George D. LeMaitre after he invented a new valvulotome, run since 2004 by his son George W. LeMaitre, with insiders still holding 8.1%. The moat is niche economics plus regulation — "too small for the giants, but too complex for generic manufacturers", and "once LeMaitre's devices are in the Operator Room, they tend to stay there." Quality metrics: gross margin 71.0%, ROIC 21.3%, net margin 22.1%, FCF/net income 124.2%, net cash, goodwill 11.0% of assets, CAPEX 2.9% of sales; revenue +14.6% / EPS +20.6% a year over five years; Owner's Earnings +21.6% (5yr) and +20.3% (10yr). Three failures are recorded rather than argued away: ROE 14.9% (bar >20%), SBC 14.0% of net income, 15.6% on a five-year average (bar <10%), and a reverse DCF demanding 16.1% FCF growth for ten years — flagged as unrealistic. Valuation splits two-to-one in favour: 32.5x forward against a 38.0x ten-year average, an Earnings Growth Model return of 11.7% (13% EPS growth + 1% yield, multiple fading 32.5x → 25.0x). Verdict: "Lemaitre Vascular is an amazing company. It's the perfect example of a Tiny Titan" — a small-cap idea, with no purchase, target price or portfolio decision attached.	read ↗

Two qualifications on the Positive stance. (1) The title question is not answered. "Should you buy LeMaitre Vascular?" ends at "an amazing company" with no fair value, no entry price and no rating — unlike the HEICO case, which scored 7.8/10 and published an explicit pass, or the FICO dive, which declined at a named $901. The stance here reads the weight of the evidence: 12 of 15 thresholds cleared, two of three valuation methods green, and a warm conclusion. (2) It is a Tiny Titans piece — the closed, waiting-list small-cap product — so this is not a Portfolio candidate, in the same category as Perimeter Solutions. The two failing quality tests are worth carrying forward: a 15.6% five-year SBC bill is the same objection that killed FICO at 22%, and it is not restated into the multiple here.

2. Talking points

The business, and why nobody covers it

"LeMaitre Vascular makes tools that help doctors fix blood vessels… Their tools are used to treat problems in blood vessels outside the heart and brain" — over 100 devices across grafts, stents, angioplasty balloons, patches and surgical instruments.
One reporting segment only: Peripheral Vascular Devices, for "aneurysms, blockages, and varicose veins."
Origin story with the moat built in: founder George D. LeMaitre was a vascular surgeon who invented a valvulotome in 1983 to treat his own patients.

The moat is the size of the market, not the size of the company

"Rather than competing head-on with medtech giants like Medtronic or Boston Scientific, they focus solely on an interesting niche market: peripheral vascular surgery. It's a niche that's too small for the giants, but too complex for generic manufacturers."
Reinforced by regulation: FDA and CE approvals "can take years and can cost millions of dollars", and "switching suppliers means retesting, retraining, and risking patient safety."
The conclusion is stated as a physical fact: "once LeMaitre's devices are in the Operator Room, they tend to stay there."

A serial acquirer hiding inside a device company

"LeMaitre currently owns 30+ subsidiaries and continues to grow via a disciplined roll-up acquisition strategy, targeting small, profitable vascular device companies globally."
The structural advantages named are the archive's standard serial-acquirer list: a fragmented market, long sales cycles favouring incumbents, surgeon brand loyalty, and distribution synergies.
The distribution asset is specific: a 100+ strong salesforce across hospitals and surgical centres, which is what makes each small acquisition worth more inside LeMaitre than outside it.

Three tailwinds, sized

Ageing populations ("more patients = more surgeries"), the shift to minimally invasive technique, and emerging-market access to surgery.
The numbers attached: vascular-surgery tools growing 6-7% a year, minimally invasive procedures 8-9% in key areas.
Note this is a mid-single-digit end market — the growth above it has to come from share gain and acquisitions, which is what makes the reverse-DCF hurdle bite.

The failures are printed, not smoothed

ROE 14.9% against a >20% bar — marked ❌ in the same block that marks ROIC 21.3% ✅. The gap between the two is the balance sheet's net cash, which flatters ROIC and depresses ROE.
SBC at 14.0% of net income, 15.6% on a five-year average, against a <10% bar: "LeMaitre Vascular uses a lot of Stock-Based Compensation, which is negative to see as an investor."
Reverse DCF: 16.1% required FCF growth for ten years — flagged unrealistic in the author's own summary line.

The one place SBC is handled properly

Inside the reverse DCF: "The expected Free Cash Flow of the next 12 months equals $63.4 million. We subtract the Stock-Based Compensation ($6.6 million) to arrive at FCF in year 1 of $56.8 million."
The headline 32.5x forward PE is not restated for the same charge — the identical inconsistency the May Arista dive shows and the FICO dive corrects.
Restating here would move the multiple by roughly a tenth, which is not decisive — but the discipline should not be selective.

The Earnings Growth Model, with its assumptions on show

"EPS growth: 13% per year over the next 10 years; Dividend Yield: 1%; Forward PE to decline from 32.5x to 25.0x. Expected yearly return = 13% + 1% + 0.1((25.0x – 32.5x)/32.5x) = 11.7%."
The 13% assumption is itself a haircut — analysts' long-term estimate is 21.5%, and the article restates the standing caveat that "analysts are usually too optimistic."
A multiple assumed to fall from 32.5x to 25.0x is the conservative move that keeps the model honest; it costs about 2.3 points of annual return.

Succession, named as the live risk

Six risks are listed; the one specific to this business is the second-generation founder: "George W. LeMaitre has been at the helm for two decades. What happens when it's time for a leadership transition? Succession planning will be key."
Also flagged: single-domain concentration, small-cap fragility ("one failed acquisition or product recall could have a large impact"), integration risk, reimbursement/regulatory change, and — last on the list — "rich valuation levels."
Compare the Judges Scientific entry nine days later, where exactly this transition is happening in real time.

What the piece is for

It opens and closes with the same call to action: LeMaitre is "the perfect example of a Tiny Titan", the doors are closed, join the waiting list and receive "a list of 94 companies with 10x potential."
A free, full-length case published as a shop window for a closed paid product — worth registering as a product mechanic alongside the Best Buys and Buy-Hold-Sell formats.

3. In plain English

A jargon-free summary of the thesis behind each argued name. (Renders on each name's consolidated page.)

LMAT — LeMaitre Vascular Positive

LeMaitre makes the instruments and implants surgeons use when they operate on blood vessels in the legs, arms and neck — the arteries and veins outside the heart and brain. Grafts to replace a damaged section of vessel, patches to close one, balloons to open a blockage, and the small tool the founder invented in 1983 to cut open stuck valves inside veins. Over a hundred products, sold straight to hospitals.

It has done this quietly and very well: $10,000 put in at the 2006 flotation would be $161,460 today against $98,690 in the S&P 500, and it is still only a $1.9 billion company.

The reason it can earn 71 cents of gross profit on every dollar of sales is the shape of its market rather than any single clever product. Peripheral vascular surgery is too small a business for Medtronic or Boston Scientific to bother fighting over, and too specialised and too regulated for a cheap generic manufacturer to enter — every device needs years of approvals, and a hospital that changes supplier has to retest everything and retrain its surgeons on something that can kill a patient if it fails. So once a LeMaitre device is in the operating room it tends to stay there. On top of that the company keeps buying up small rivals — more than 30 so far — and pushes their products through its own 100-person salesforce, which is worth far more inside LeMaitre than it was outside.

Slegers runs it through his fifteen-question checklist and it passes twelve of them, scoring 8.0 out of 10. What it fails on is worth knowing. Staff are paid in shares worth about 15% of profits — a real cost to existing owners, and above his 10% limit. Return on equity is 14.9%, below his 20% bar. And most importantly, his reverse calculation says the current share price already assumes the company's cash flow grows 16% a year for the next decade, which he marks as unrealistic. Against that, the shares are cheaper than their own ten-year average and his return model gets to 11.7% a year.

So: an excellent, genuinely obscure business, priced as though the good news continues without interruption — and a piece written for the closed small-cap service, not as a candidate for the main portfolio. The article asks "should you buy?" in the title and never answers it, which is itself the honest signal.

Summary derived from the archived Compounding Quality post (text in transcript.txt) for personal study. Not investment advice. © Compounding Quality / Pieter Slegers for source material.